Deals In Depth: May 2016
Biogen signed a $2bn deal with UPenn focused on gene therapy; Thermo Fisher made its second major acquisition this year, paying over $4bn for FEI. Early-stage venture funding and FOPOs made up more than half of the month's total $1.6bn in biopharma financing, and big debt offerings from Wright Medical and Teleflex dominated device financing.
You may also be interested in...
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.